Report cover image

Immune Checkpoint Inhibitors for Lung Cancer Market by Products (Atezolizumab, Durvalumab, Nivolumab), Type (CTLA-4 Inhibitors, PD-1 Inhibitors, PD-L1 Inhibitors), End-Users - Global Forecast 2024-2030

Publisher 360iResearch
Published Jan 15, 2024
Length 199 Pages
SKU # IRE18444747

Description

Immune Checkpoint Inhibitors for Lung Cancer Market by Products (Atezolizumab, Durvalumab, Nivolumab), Type (CTLA-4 Inhibitors, PD-1 Inhibitors, PD-L1 Inhibitors), End-Users - Global Forecast 2024-2030


The Immune Checkpoint Inhibitors for Lung Cancer Market size was estimated at USD 1.01 billion in 2023 and expected to reach USD 1.15 billion in 2024, at a CAGR 14.55% to reach USD 2.62 billion by 2030.

Global Immune Checkpoint Inhibitors for Lung Cancer Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Immune Checkpoint Inhibitors for Lung Cancer Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Immune Checkpoint Inhibitors for Lung Cancer Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Immune Checkpoint Inhibitors for Lung Cancer Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AstraZeneca PLC, Bayer AG, BeyondSpring Pharmaceuticals Inc., BioLineRx Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline PLC, IQVIA Inc., Jazz Pharmaceuticals PLC, Laboratory Corporation of America Holdings, Merck KGaA, Mirati Therapeutics Inc., and Ono Pharmaceutical Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Immune Checkpoint Inhibitors for Lung Cancer Market to forecast the revenues and analyze trends in each of the following sub-markets:

Products
Atezolizumab

Durvalumab

Nivolumab

Pembrolizumab

Type
CTLA-4 Inhibitors

PD-1 Inhibitors

PD-L1 Inhibitors

End-Users
Academic & Research Institutes

Hospitals

Pharmaceutical & Biotechnology Companies

Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam

Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Immune Checkpoint Inhibitors for Lung Cancer Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Immune Checkpoint Inhibitors for Lung Cancer Market?
3. What are the technology trends and regulatory frameworks in the Immune Checkpoint Inhibitors for Lung Cancer Market?
4. What is the market share of the leading vendors in the Immune Checkpoint Inhibitors for Lung Cancer Market?
5. Which modes and strategic moves are suitable for entering the Immune Checkpoint Inhibitors for Lung Cancer Market?

Note: PDF & Excel + Online Access - 1 Year

Table of Contents

199 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Immune Checkpoint Inhibitors for Lung Cancer Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. High prevalence of lung cancer necessitating immune checkpoint inhibitors
5.1.1.2. Government investment in cancer research and treatment
5.1.1.3. Increasing product approval by regulatory agencies
5.1.2. Restraints
5.1.2.1. Limited affordability and reimbursement for immune checkpoint inhibitor therapies
5.1.3. Opportunities
5.1.3.1. Development of promising predictive biomarkers for immune checkpoint inhibitor therapies
5.1.3.2. Combination of immune checkpoint inhibitors with other cancer therapies
5.1.4. Challenges
5.1.4.1. Lack of research standardization of checkpoint inhibitors
5.1.4.2. Possible side-effects of immune checkpoint inhibitors
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Immune Checkpoint Inhibitors for Lung Cancer Market, by Products
6.1. Introduction
6.2. Atezolizumab
6.3. Durvalumab
6.4. Nivolumab
6.5. Pembrolizumab
7. Immune Checkpoint Inhibitors for Lung Cancer Market, by Type
7.1. Introduction
7.2. CTLA-4 Inhibitors
7.3. PD-1 Inhibitors
7.4. PD-L1 Inhibitors
8. Immune Checkpoint Inhibitors for Lung Cancer Market, by End-Users
8.1. Introduction
8.2. Academic & Research Institutes
8.3. Hospitals
8.4. Pharmaceutical & Biotechnology Companies
9. Americas Immune Checkpoint Inhibitors for Lung Cancer Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Immune Checkpoint Inhibitors for Lung Cancer Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.
10. South Korea
10.
11. Taiwan
10.
12. Thailand
10.
13. Vietnam
11. Europe, Middle East & Africa Immune Checkpoint Inhibitors for Lung Cancer Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.
10. Nigeria
11.
11. Norway
11.
12. Poland
11.
13. Qatar
11.
14. Russia
11.
15. Saudi Arabia
11.
16. South Africa
11.
17. Spain
11.
18. Sweden
11.
19. Switzerland
11.
20. Turkey
11.
21. United Arab Emirates
11.
22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AbbVie Inc.
13.1.2. AstraZeneca PLC
13.1.3. Bayer AG
13.1.4. BeyondSpring Pharmaceuticals Inc.
13.1.5. BioLineRx Ltd.
13.1.6. Bristol-Myers Squibb Company
13.1.7. F. Hoffmann-La Roche Ltd.
13.1.8. Genentech, Inc.
13.1.9. GlaxoSmithKline PLC
13.1.
10. IQVIA Inc.
13.1.
11. Jazz Pharmaceuticals PLC
13.1.
12. Laboratory Corporation of America Holdings
13.1.
13. Merck KGaA
13.1.
14. Mirati Therapeutics Inc.
13.1.
15. Ono Pharmaceutical Co., Ltd.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET RESEARCH PROCESS
FIGURE 2. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2023 VS 2030
FIGURE 3. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET DYNAMICS
FIGURE 7. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2023 VS 2030 (%)
FIGURE 8. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 10. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 12. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us